Among other things, there can be no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with the results to date, that Zepbound will receive additional regulatory approvals, or that Zepbound will be commercially successful or that we will meet anticipated timelines for its commercialization
however, there are some PK/PD differences to consider in some special populations
In January, Jaguar Health subsidiary Napo Pharmaceuticals filed a patent application for Mytesi to treat the GI side effects common with GLP-1 and GIP treatments used for obesity
Gentle activity increases blood flow, prevents adhesions, maintains flexibility, and helps the body lay down collagen in proper alignment
Its seen as a crutch or the easy way out, when that couldnt be further from the truth